Abstract:Glycogen synthase kinase-3 (GSK-3) dysregulation has been implicated in nigral dopaminergic neurodegeneration, one of the main pathological features of Parkinson's disease (PD). The two isoforms, GSK-3 alpha and GSK-3 beta, have both been suggested to play a detrimental role in neuronal death. To date, several studies have focused on the role of GSK-3 beta on PD pathogenesis, while the role of GSK-3 alpha has been largely overlooked. Here, we reportin situobservations that both GSK-3 alpha and GSK-3 beta are dephosphorylated at a negatively acting regulatory serine, indicating kinase activation, selectively in nigral dopaminergic neurons following exposure of mice to 1-methyl-4-pheny-1,2,3,6-tetrahydropyridine (MPTP). To identify whether GSK-3 alpha and GSK-3 beta display functional redundancy in regulating parkinsonian dopaminergic cell death, we analysed dopaminergic neuron-specific Gsk3anull (Gsk3a(Delta Dat)) and Gsk3b null (Gsk3b(Delta Dat)) mice, respectively. We found that Gsk3b(Delta Dat), but not Gsk3a(Delta Dat), showed significant resistance to MPTP insult, revealing non-redundancy of GSK-3 alpha and GSK-3 beta in PD pathogenesis. In addition, we tested the neuroprotective effect of tideglusib, the most clinically advanced inhibitor of GSK-3, in the MPTP model of PD. Administration of higher doses (200 mg/kg and 500 mg/kg) of tideglusib exhibited significant neuroprotection, whereas 50 mg/kg tideglusib failed to prevent dopaminergic neurodegeneration from MPTP toxicity. Administration of 200 mg/kg tideglusib improved motor symptoms of MPTP-treated mice. Together, these data demonstrate GSK-3 beta and not GSK-3 alpha is critical for parkinsonian neurodegeneration. Our data support the view that GSK-3 beta acts as a potential therapeutic target in PD and tideglusib would be a candidate drug for PD neuroprotective therapy.

GSK-3 in Neurodegenerative Diseases

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

GSK3: A potential target and pending issues for treatment of Alzheimer's disease

The Role of Glycogen Synthase Kinase 3 Beta in Neurodegenerative Diseases

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer's Disease

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

Association of Glycogen Synthase Kinase-3Β with Parkinson’s Disease (Review)

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

GSK3 in Alzheimer's Disease: Mind the Isoforms

Regulation of Glycogen Synthase Kinase-3β by Phosphorylation and O-β-Linked N-Acetylglucosaminylation: Implications on Tau Protein Phosphorylation

Mis-regulation of GSK-3β causes axonal microtubule curling through Shot and Tau

β-Amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3

Glycogen synthase kinase 3 and neurophysiology

The Key Roles of GSK-3β in Regulating Mitochondrial Activity

Glycogen synthase kinase-3 regulates production of amyloid-β peptides and tau phosphorylation in diabetic rat brain.

Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation

Glycogen synthase kinase-3 (GSK3): Regulation, actions and diseases.

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

GSK3 is a Central Player in Retinal Degenerative Diseases but a Challenging Therapeutic Target

GSK-3β Contributes to Parkinsonian Dopaminergic Neuron Death: Evidence from Conditional Knockout Mice and Tideglusib.